1 – 16 of 16
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Precision Diagnostics in Myeloid Malignancies : Development and Validation of a National Capture-Based Gene Panel
(
- Contribution to journal › Article
- 2023
-
Mark
m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis
(
- Contribution to journal › Article
-
Mark
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
(
- Contribution to journal › Article
- 2022
-
Mark
Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome
(
- Contribution to journal › Article
- 2021
-
Mark
Precisionsmedicin standard vid flera hematologiska sjukdomar
(
- Contribution to journal › Article
- 2018
-
Mark
Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells
(
- Contribution to journal › Article
- 2016
-
Mark
The european hematology association roadmap for european hematology research : A consensus document
(
- Contribution to journal › Article
- 2014
-
Mark
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
(
- Contribution to journal › Article
-
Mark
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
(
- Contribution to journal › Article
-
Mark
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo.
(
- Contribution to journal › Article
- 2011
-
Mark
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
(
- Contribution to journal › Article
- 2010
-
Mark
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
(
- Contribution to journal › Article
- 2009
-
Mark
Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities
(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following Myelodysplastic syndrome
(
- Contribution to journal › Article
- 2006
-
Mark
A pharmacodynamic study of 5-azacytidine in the P39 cell line
(
- Contribution to journal › Article
- 2002
-
Mark
Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.
(
- Contribution to journal › Article